Surya Pharmaceutical Ltd
Surya Pharmaceuticals Ltd. ventures as a pharmaceutical company. The businesses include Contract Manufacturing, Custom Synthesis, FTE Research, and the manufacture and marketing of pharmaceuticals products and services to clients worldwide. Surya Pharmaceuticals' wide range of product portfolio includes Active Pharmaceutical Ingredients (APIs), Fine Intermediates, Finished Drug Formulations (FDFs), Phyto Pharmaceuticals and CRAMS.
- Market Cap ₹ Cr.
- Current Price ₹ 0.16
- High / Low ₹ /
- Stock P/E
- Book Value ₹ -3.87
- Dividend Yield 0.00 %
- ROCE -11.9 %
- ROE -402 %
- Face Value ₹ 1.00
Pros
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of -58.9% over last 3 years.
- Company has high debtors of 915 days.
- Working capital days have increased from 1,431 days to 3,768 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | |
|---|---|---|---|---|
| 1,142 | 1,656 | 1,746 | 90 | |
| 983 | 1,400 | 1,913 | 255 | |
| Operating Profit | 159 | 257 | -166 | -165 |
| OPM % | 14% | 15% | -10% | -183% |
| 13 | 3 | -41 | -35 | |
| Interest | 63 | 109 | 187 | 222 |
| Depreciation | 21 | 28 | 39 | 68 |
| Profit before tax | 88 | 123 | -434 | -490 |
| Tax % | 16% | 24% | -30% | -32% |
| 74 | 93 | -305 | -333 | |
| EPS in Rs | 50.81 | 4.83 | -14.99 | -15.71 |
| Dividend Payout % | 3% | 4% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -57% |
| TTM: | -95% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -59% |
| Last Year: | -402% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | |
|---|---|---|---|---|
| Equity Capital | 16 | 22 | 25 | 25 |
| Reserves | 290 | 496 | 203 | -103 |
| 719 | 1,476 | 1,898 | 2,171 | |
| 381 | 236 | 163 | 57 | |
| Total Liabilities | 1,406 | 2,230 | 2,289 | 2,149 |
| 238 | 434 | 791 | 727 | |
| CWIP | 200 | 245 | 18 | 19 |
| Investments | 0 | 9 | 59 | 55 |
| 968 | 1,542 | 1,421 | 1,349 | |
| Total Assets | 1,406 | 2,230 | 2,289 | 2,149 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | |
|---|---|---|---|---|
| 163 | 72 | 366 | 133 | |
| -148 | -270 | -180 | -8 | |
| -4 | 195 | -186 | -133 | |
| Net Cash Flow | 11 | -3 | -0 | -8 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | |
|---|---|---|---|---|
| Debtor Days | 50 | 67 | 52 | 915 |
| Inventory Days | 271 | 303 | 174 | 1,152 |
| Days Payable | 109 | 25 | 16 | 61 |
| Cash Conversion Cycle | 212 | 345 | 210 | 2,007 |
| Working Capital Days | 185 | 301 | 224 | 3,768 |
| ROCE % | 15% | -12% | -12% |
Documents
Announcements
No data available.